ArticleJoint bone spine2020
Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy.
Article in Joint bone spine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis.Rheumatology international · 2021Pooled it
- Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data.Autoimmunity reviews · 2021Pooled it
- The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - A systematic review of the literature.Journal of autoimmunity · 2021Pooled it
- Molecular Roadmap of COVID-19: From Viral Entry to Therapeutic Targets.Chemistry & biodiversity · 2026Review
- Determinants of COVID-19 Disease Severity-Lessons from Primary and Secondary Immune Disorders including Cancer.International journal of molecular sciences · 2023Review
- The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases.Journal of clinical medicine · 2022Article
- Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic.The archives of bone and joint surgery · 2022Article
- Article
- Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by SingerAnnals of the rheumatic diseases · 2022Article
- Observational
- The effect of COVID-19 pandemic in a large series of patients with Takayasu arteritis.Turkish journal of medical sciences · 2022Article
- Article
- COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients.Dermatologic therapy · 2022Article
- Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019.The Korean journal of internal medicine · 2022Article
- Systematic assessment of the humoral response against SARS-CoV-2 in a French cohort of 283 patients with rheumatic diseases.Joint bone spine · 2022Article
- Article
- Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases in Qatar.Qatar medical journal · 2022Article
- COVID-19 from a rheumatology perspective: bibliometric and altmetric analysis.Rheumatology international · 2021Review
- Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up.Clinical rheumatology · 2021Article
- Association between previous rheumatoid arthritis and COVID-19 and its severity: a nationwide cohort study in South Korea.BMJ open · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study is to determine the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) among adult patients treated with biologic agents or small molecules for chronic inflammatory rheumatic diseases, in particular for chronic inflammatory arthritides.
methodsTo this end, a population-based study, in the province of Udine (466,700 inhabitants, with age>15 years old, Friuli Venezia Giulia region, Italy) was planned. The primary outcome was the prevalence of COVID-19 in the first two months of the outbreak. All the rheumatic patients treated with biologic agents or small molecules in the last 6 months in our province were included (N=1051).
resultsFrom February 29 to April 25, 2020, 4 adult patients (4/1051, i.e. 3.8/1000, 95% Confidence Interval 1.5-9.7/1000) were registered as swab test positive by PCR for COVID-19. Overall, a total of 47/1051 (4.5%) cases were tested for COVID-19 by PCR in the same period, and 15 of them due to symptoms compatible with COVID-19. In the general population, the prevalence was 937 cases/466700 (2/1000, 95% Confidence Interval 1.9-2.1/1000, P-value=0.33, chi square test), and 20,179/466,700 (4.3%) swab tests for COVID-19 were performed.
conclusionThe risk of COVID-19 in rheumatic patients under biologic agents or small molecules does not appear different from that observed in the general population. Patients should be informed to safely proceed with their treatment and follow the rules for self-protection to COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.